NEW APPROACHES TO TREATMENT BY GASTROINTESTINAL CANCER

胃肠癌治疗新方法

• 批准号: 3093403
• 负责人: CHARLES G. MOERTEL
• 金额: $ 97.83万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-03-01 至 1990-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3093403
• 关键词: combination cancer therapy; combination chemotherapy; gastrointestinal neoplasms; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy

Over the next five years of this Program Project we will continue to make strong efforts to bring together in a coordinated unit the clinical research disciplines and related laboratories of the Mayo Clinic for the purpose of improving both palliative and curative treatment of human gastrointestinal cancer. The following specific areas will be addressed: 1) Treatment of colorectal cancer. 2) Treatment of the less common gastrointestinal carcinomas and 3) Gastrointestinal Cancer Laboratory Science. We continue to place special emphasis on the development and testing of innovative approaches to regional disease and surgical adjuvant therapy with cure as a specific end point. Of primary importance will be the integration directly into clinical research programs of sophisticated laboratory endeavors in cancer pharmacology, cytogenetics and immunology. We will continue to utilize the particular strengths of this program which include an unexcelled depth of experience in gastrointestinal clinical cancer research; a devoted clinical research team including all concerned disciplines; the exceptionally large cancer patient population available at the Mayo Clinic permitting meaningful studies to be performed in a timely fashion; the uniquely large population of newly diagnosed gastrointestinal cancer permitting conduct of early disease studies; an extraordinarily large population of patients with less common cancers; strong relationships with community clinics in our region through the North Central Cancer Treatment Group permitting a continuum of management and expanded Phase III trials utilizing the same data base; a well developed Mayo Cancer Center Statistical Unit which is involved in all phases of our studies to insure sound protocol design, consistent data quality, and informed and objective data analysis; and ready availability of large amount of tissue and laboratory materials for basic laboratory study. We believe these ingredients combined with our established productivity and our documented accomplishment during the first two and one-half years of this grant provide maximum confidence that the work proposed will meet highest scientific standards and will be conducted with unexcelled quality and cost effectiveness.

在该计划项目的未来五年中，我们将继续 作出强有力的努力，把 梅奥的临床研究学科和相关实验室 临床论治兼治 治疗人类胃肠道癌症。以下是 将解决具体领域：1)治疗结直肠 癌症。2)较少见的胃肠道疾病的治疗 癌症和3)胃肠道肿瘤实验室科学。 我们继续特别重视发展和 测试针对地区性疾病和外科手术的创新方法 以治愈为特定终点的辅助治疗。主要的 重要的是直接整合到临床研究中 先进的癌症实验室项目 药理学、细胞遗传学和免疫学。我们将继续 利用该计划的特殊优势，包括 无与伦比的胃肠道临床癌症经验 研究；一个专注的临床研究团队，包括所有相关人员 学科；异常庞大的癌症患者群体 在梅奥诊所提供，允许有意义的研究 及时上演；独一无二的庞大人口 新诊断的胃肠道癌症允许进行 早期的疾病研究；一个异常庞大的人口 癌症不太常见的患者；与 从中北部癌症看我区的社区诊所 治疗集团允许连续的管理和 利用相同数据库的扩展的第三阶段试验；一口井 开发了梅奥癌症中心统计单位，参与了 在我们确保合理协议设计的研究的所有阶段中， 一致的数据质量，以及知情和客观的数据分析； 和现成的大量组织和实验室 基础实验室研究的材料。我们相信这些成分 结合我们既定的生产力和我们记录的 头两年半的成就 格兰特提供了最大的信心，即拟议的工作将 达到最高科学标准，将与 无与伦比的质量和成本效益。